| 摘要 |
<p>Disclosed herein is the use of 15-oxo prostaglandin fatty acid derivatives (prostones) for the manufacture of a medicament for treating esophagitis in a mammalian subject, wherein the fatty acid derivative is (-)-7-[(2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-yl]heptanoic acid (lupiprostone/SPI-0211), (-)-7-{ (2R,4aR,5R,7aR)-2-[(3S)-1,1-difluoro-3-methylpentyl-2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-yl} heptanoic acid (cobiprostone), or (-)-7-[(1R,2R)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]heptanoic acid. The disclosure also relates to the use of the compounds for modulating cytokine activity.</p> |
